Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

11-09	Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications	CI
11-03	Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026	CI

Market Cap	63.66B 57.57B 53.14B 48.1B 90.76B 5,984B 93.48B 638B 253B 3,199B 239B 234B 10,183B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 73.22B 67.58B 61.17B 115B 7,611B 119B 811B 322B 4,069B 304B 297B 12,952B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

11-09	Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications	CI
11-03	Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026	CI
10-21	Allergan Aesthetics presents its latest scientific advances
09-29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI
09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
09-02	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-08	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
04-01	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-13	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news: Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

10-21	Allergan Aesthetics présente ses dernières avancées scientifiques
20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020
Andres Rodrigo BRD	Director/Board Member	-	08/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/5/20	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
8/5/20	Adriane Brown	Issuer sale	Director	2,916	0.0009%
8/5/20	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	-0.70%	+4.58%	+40.23%	+138.79%	1,280B
JOHNSON & JOHNSON	+1.11%	+4.11%	+45.85%	+92.54%	675B
ABBVIE INC.	-0.18%	+2.15%	+26.25%	+112.46%	521B
ROCHE HOLDING AG	+1.14%	+3.78%	+39.98%	+71.70%	386B
MERCK & CO., INC.	-0.16%	+0.01%	+60.69%	+44.94%	363B
NOVARTIS AG	+1.11%	+0.07%	+28.19%	+60.05%	301B
ASTRAZENECA PLC	+0.24%	-0.67%	+3.45%	+38.06%	286B
AMGEN INC.	-0.22%	+1.47%	+38.89%	+74.73%	253B
GILEAD SCIENCES, INC.	-1.05%	+0.23%	+36.10%	+121.22%	211B
Average	+0.13%	+0.37%	+35.52%	+83.83%	434B
Weighted average by Cap.	+0.06%	+0.58%	+37.53%	+97.32%

	2018	2019
Net sales	15.79B 14.28B 13.18B 11.93B 22.51B 1,484B 23.18B 158B 62.86B 793B 59.25B 57.99B 2,525B	16.09B 14.55B 13.43B 12.16B 22.94B 1,512B 23.63B 161B 64.06B 809B 60.38B 59.1B 2,574B
Net income	-5.1B -4.61B -4.25B -3.85B -7.27B -479B -7.48B -51.06B -20.29B -256B -19.13B -18.72B -815B	-5.27B -4.77B -4.4B -3.98B -7.52B -496B -7.74B -52.81B -20.99B -265B -19.78B -19.36B -843B
Net Debt	21.89B 19.8B 18.27B 16.54B 31.21B 2,058B 32.15B 219B 87.16B 1,100B 82.16B 80.41B 3,502B	17.3B 15.65B 14.44B 13.07B 24.67B 1,627B 25.41B 173B 68.9B 870B 64.95B 63.56B 2,768B